他汀类药物在慢性肝病中的作用  

Role of statins in chronic liver disease

作　　者：杨希坤 李晖[1] 曾子键 吴旋 王凯鑫 YANG Xikun;LI Hui;ZENG Zijian;WU Xuan;WANG Kaixin(Central Laboratory,The Affiliated Hospital of Chengdu University of Traditional Chinese Medicine,Chengdu 610072,China;School of Clinical Medicine,Chengdu University of Traditional Chinese Medicine,Chengdu 610072,China)

机构地区：[1]成都中医药大学附属医院中心实验室,成都610072 [2]成都中医药大学临床医学院,成都610072

出　　处：《临床肝胆病杂志》2024年第10期2104-2108,共5页Journal of Clinical Hepatology

基　　金：国家自然科学基金面上项目(82274323)。

摘　　要：慢性肝病是肝脏由炎症、纤维化,向肝硬化、肝癌进展的“魔鬼三部曲”,是全球肝病科医生面临的巨大挑战。他汀类药物自问世以来,在心血管疾病和高脂血症治疗中发挥了巨大作用,近年来其同样显示出在慢性肝病中具有改善肝脂肪变性、抗炎、调节肝星状细胞表型、降低门静脉压力、改善肝脏微循环等关键环节的重要潜力。本文综述了他汀类药物在慢性肝病基础和临床研究中的最新进展,为慢性肝病的研究和防治提供新的见解。Chronic liver disease is the“devil’s trilogy”in which the liver progresses from inflammation and fibrosis to liver cirrhosis and hepatocellular carcinoma,which poses a great challenge for hepatologists worldwide.Statins have played a significant role in the treatment of cardiovascular diseases and hyperlipidemia since their introduction,and in recent years,they have also demonstrated the potential to improve hepatic steatosis,exert an anti-inflammatory effect,regulate the phenotype of hepatic stellate cells,reduce portal venous pressure,and improve hepatic microcirculation in chronic liver disease.This article reviews the latest advances in the basic and clinical studies of statins in chronic liver disease,in order to provide new insights into the research,prevention,and treatment of chronic liver disease.

关 键 词：羟甲基戊二酰基COA还原酶抑制剂 肝纤维化 肝硬化 癌 肝细胞 

分 类 号：R575[医药卫生—消化系统]